Now Hiring - Healthcare Senior Regional Business Manager in Chicago, IL

Here at Glaukos, we recognize the deep significance and profound meaning that comes from knowing that we can make a meaningful difference by helping improve the eyesight of people worldwide. Because we’re a rapidly growing company with a dynamic, fast-paced culture, employees here are empowered with more diverse and enriching challenges than might not be possible at a larger company.

Base Salary Range: $94,800 - $137,600

Company: Glaukos Industry: Medical Technology and Pharmaceutical Level: Full time Location: Chicago, IL Compensation: Base Salary Range: $94,800 - $137,600 OVERVIEW Position Summary The Senior RBM is responsible for training and helping to integrate the iStent technology into their assigned practice. You will achieve quarterly sales objectives by selling to targeted ophthalmic surgeons within the assigned territory. The Senior RBM will attend surgeries and help the surgeon to achieve the desired surgical outcomes for the patient. The Senior RBM will achieve these standards by focusing on the customer while managing the territory for the best return on investment. Compensation Compensation for each successful candidate will be based on several factors, which may include qualifications, experience, education, talent availability, and local market conditions. Range listed is not inclusive of additional compensation such as bonus, equity, or additional benefits. › RESPONSIBILITIES Sales Prospecting by initiating sales calls to sell the surgeon on the Glaukos iStent and initiate surgical wet-labs to train the surgeon. Attend targeted meetings as directed to increase sales lead opportunities and protect existing business. Performance Attend the initial iStent surgeries until the surgeon is confident and skilled to perform the cases. Assist Work with the surgeon and staff to educate and assist in getting proper reimbursement for the Glaukos iStent. Training Train the office staff and the doctor to recognize and convert patients to the iStent technology using Glaukos Practice System (GPS). REQUIREMENTS Procedure Ability to comply with procedures and processes. Communication Ability to communicate with KOLs and surgeons both in the OR and outside. Budget Ability to work within a budget. Experience 3 plus years of ophthalmic medical sales experience (either surgical or pharmaceutical). Experience developing and expanding new territories. Proven experience meeting and exceeding targeted goals. Experience with tracking CRM software. The preferred candidate would have both ophthalmic surgical and pharmaceutical experience. Build Ability to build relationships and interact with all levels. Proven ability to build and retain customer base. Education Bachelor’s degree or equivalent experience. Concentration in Business or Marketing preferred. Procedure Ability to comply with procedures and processes. Communication Ability to communicate with KOLs and surgeons both in the OR and outside. Budget Ability to work within a budget. Experience 3 plus years of ophthalmic medical sales experience (either surgical or pharmaceutical). Experience developing and expanding new territories. Proven experience meeting and exceeding targeted goals. Experience with tracking CRM software. The preferred candidate would have both ophthalmic surgical and pharmaceutical experience. Build Ability to build relationships and interact with all levels. Proven ability to build and retain customer base. Education Bachelor’s degree or equivalent experience. Concentration in Business or Marketing preferred. ‹ › ABOUT US Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Our company was the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure which revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in September 2018 and iStent inject® W in September 2020. In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for glaucoma, corneal health, and retinal diseases.